Phase I study of intratumoral injection of talimogene laherparepvec for the treatment of advanced pancreatic cancer
Mené sur 9 patients atteints d'un adénocarcinome canalaire du pancréas de stade avancé et réfractaire aux traitements, cet essai de phase I détermine la dose maximale tolérée de talimogène laherparepvec en injection intratumorale
Pancreatic ductal adenocarcinoma (PDAC) presents a redoubtable challenge due to late-stage diagnosis and limited treatment options, necessitating innovative therapeutic strategies.Here, we report our results investigating the safety and efficacy of talimogene laherparepvec (T-VEC), an FDA-approved oncolytic herpes simplex virus type 1, in patients with advanced PDAC. Nine patients with treatment-refractory advanced PDAC received escalating doses of T-VEC via endoscopic injection.While no objective responses were observed, stable disease was achieved in 44% of patients, with a median overall survival of 7.8 months, including one patient who survived 28 months. Adverse events were manageable, with the maximum tolerated dose determined to be 108 PFU/mL.Our findings underscore the feasibility of intratumoral T-VEC administration in advanced PDAC. Further investigation, particularly in combination with immunotherapies administered systemically is warranted to more optimally assess T-VEC in this challenging malignancy.ClinicalTrials.gov Identifier: NCT03086642.
https://academic.oup.com/oncolo/advance-article/doi/10.1093/oncolo/oyae200/7914921